Wegovy: Semaglutide Reduces Migraine Severity, Especially in Women

A recent study from Denmark has highlighted the potential benefits of semaglutide, a medication primarily used for weight management, in alleviating migraine symptoms among women. The findings suggest that women starting semaglutide may experience a significant reduction in their reliance on triptans, a commonly prescribed medication for migraine relief.

Conducted by researchers from the University of Southern Denmark in collaboration with Novo Nordisk, the study analyzed data from Danish health registries, covering nearly 150,000 adults who began semaglutide treatment between December 2022 and June 2024. Of these participants, approximately two-thirds were women. The researchers tracked participants’ triptan usage over a two-year period prior to starting semaglutide and continued to monitor their usage for one year afterward.

The analysis revealed a notable trend: while triptan usage had been increasing prior to the introduction of semaglutide, it began to decline after the medication was initiated. By the one-year mark, women showed an approximate 8% decrease in triptan consumption. However, no significant changes were observed among male participants, indicating that the benefits of semaglutide may be more pronounced for women.

The research found that younger adults aged 18 to 35 experienced the most significant reductions in triptan use, suggesting that age may play a role in how patients respond to semaglutide. Additionally, those with a history of preventive migraine medication usage saw a more substantial decline in their need for triptans, indicating the medication’s potential in lessening migraine burden over time.

Experts believe that several factors might contribute to semaglutide’s efficacy in reducing migraine severity. Tom Lavin, MD, a board-certified surgeon, noted that semaglutide may help reduce inflammation and intracranial pressure, as these factors are known to influence migraine occurrences. “GLP-1 medications like semaglutide reduce inflammation throughout the body, including in the brain,” he explained, emphasizing that neuroinflammation is a significant driver of migraines.

Additionally, Jill White, PharmD, highlighted the significance of the study’s sex-specific findings, suggesting that hormonal differences and metabolic responses in women might lead to greater benefits from semaglutide. “It is possible that GLP-1-mediated metabolic or inflammatory improvements interact differently with female neuroendocrine physiology,” she stated.

Despite these promising results, experts caution that further research is essential before semaglutide can be officially recommended as a treatment for migraines. Evidence indicates that even a modest reduction in triptan usage could enhance the quality of life for migraine sufferers, particularly by alleviating the risk of medication-overuse headaches.

In conclusion, while the findings from this study present an exciting avenue for potential migraine management, more comprehensive research is needed to fully understand the implications of semaglutide in treating migraines across different populations. For now, the results offer hope that semaglutide may not only assist in weight management but also provide relief for many women suffering from migraines.